好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Specialized Neuroprognostication Program is Associated With Improved Guideline-adherence and Outcomes after Cardiac Arrest
Neuro Trauma and Critical Care
S21 - Neurocritical Care (2:12 PM-2:24 PM)
007

To determine if a specialized neuroprognostication program improves guideline-adherence, outcomes, and hospital length of stay (LOS). 

The withdrawal of life-sustaining treatment for a poor neurologic prognosis is the most common cause of death in survivors of cardiac arrest. However, neuroprognostication is conducted variably, inconsistently adheres to guidelines, and is prone to error. We implemented a novel neuroprognostication program that provides specialized inpatient consultations, hypothesizing an associated improvement in guideline-adherence, outcomes, and LOS. 

We abstracted neuroprognostication testing, outcomes, and LOS for consecutive out-of-hospital cardiac arrest patients admitted unconscious (without command-following) to our health system (both intervention and non-intervention hospitals) in the years prior to program implementation (pre; 2019-2022) and after (post; 2022-2024). For guideline-compliance, we reviewed post-arrest neuroprognostication guidelines and identified tests endorsed by all (EEG, CT, MRI, SSEP, and pupillary responses). For outcomes, we measured the frequency with which patients were discharged conscious (command-following).

Among 547 cardiac arrest patients admitted unconscious, characteristics were similar across hospitals and time (age, sex, race/ethnicity, arrest rhythm, comorbidities). Program-exposed patients underwent all guideline-compliant tests more frequently than contemporary patients at non-intervention hospitals or historical patients at the intervention hospital (23% vs 7% and 1%, respectively). The frequency of patients discharged conscious increased from 13% pre to 21% post at the intervention hospital, but not at non-intervention hospitals (15% pre to 12% post). LOS among surviving patients did not significantly change over this time at the intervention hospital (median 21.5 days [IQR 13.3-34.5] pre, 25 [17.5,35] post, p=0.75) or non-intervention hospitals (20.0 [9.8-33.1] pre, 20.5 [14.0,39.0], p=0.46).

A specialized neuroprognostication program is associated with an increase in the frequency of guideline-compliant testing, and the frequency of patients discharged conscious. Improvement in consciousness recovery does not reflect a general effect of time (as evidenced by non-intervention hospitals), nor a significant increase in program-associated LOS.

Authors/Disclosures
David J. Fischer, MD (Dept of Neurology, Hospital of University of Pennsylvania)
PRESENTER
Dr. Fischer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alphasights. Dr. Fischer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atheneum. Dr. Fischer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Becton Dickinson. Dr. Fischer has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Drazin & Warshaw. The institution of Dr. Fischer has received research support from NIH/NINDS. The institution of Dr. Fischer has received research support from 好色先生. The institution of Dr. Fischer has received research support from Neurocritical Care Society.
Saleem M. Halablab, MD Dr. Halablab has nothing to disclose.
Connor A. Law, BS Mr. Law has nothing to disclose.
Andrea L. Schneider, MD, PhD (University of Pennsylvania) Dr. Schneider has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN - Neurology.